Global Hereditary Testing Market

Hereditary Testing Market Insights

Genetic tests are classified as accessible medical tests which come in the form of kits and panels and are used to assess human genetic, lifestyle disorders, cancer, and cardiovascular diseases. The test is conducted by obtaining patients' blood samples which are then run on laboratory machines. During the forecast timeframe, growth is expected to be driven by growing expenditure on R&D activities and the rising incidence of chronic diseases worldwide. The development may be attributed to the advancement of genetic testing services and the growing demand for personalized medicine. The sequencing time and costs for genetic testing have been reduced by introducing the latest technologies in the genetic testing field. Another significant factor in the growth of this industry is the growing demand for direct-to-consumer genetic testing.

Hereditary Testing Market: By Type of Disease

The market can be segregated into hereditary non-cancer testing and hereditary cancer testing based on the type of diseases. Hereditary cancer testing will be the largest shareholder in the market owing to the increasing affordability of the tests and increasing demand for DNA test kits. Besides, the demand for early and non-invasive methods of fetal testing would drive market growth. Furthermore, the high risk of BRCA1 carriers in probable breast cancer patients, have stimulated the demand for hereditary cancer testing in the market

Lung cancer, on the other hand, is one of the common types of cancer with a relatively limited number of products to conduct an early diagnosis. This is because most lung cancer cases are not linked to genetic mutations that have been inherited. Hence, the research activities in this market are motivated by the lack of effective evidence about the heritability of cervical cancer which will drive the market growth.

Hereditary Testing Market: By Region

The European region is expected to boost market shareholder activity over the expected timeline from 2021 to 2026. On the other hand, the Asia Pacific market will expand the fastest from 2021 to 2026 because of increasing awareness of early screening of genetic disorders and cancer. Also, growing healthcare expenditure, increasing government support for research projects, and the consumption of junk food and sedentary lifestyles would also ultimately accelerate the APAC sector.

Hereditary Testing Market Share and Competitor Analysis

Myriad Genetics, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Blueprint Genetics, Agilent Technologies, Inc., Twist Bioscience, Fulgent Genetics, Inc., CENTOGENE N.V., BG Genomic, Invitae Corporation, Natera Inc., F. Hoffmann-La Roche Ltd., CooperSurgical, Inc., Thermo Fisher Scientific, Inc., Sophia Genetics, and MedGenome are the main competitors of the market.

Please note: This is not an exhaustive list of companies profiled in the report.

In April 2018, BGI Genomic introduced BGI Sentis HPV, an HPV screening tool that is used for screening for cervical cancer.